pipeline
JIN-NOVA
Certificate
NOTICE
-
Convergence of
Science & Business -
Convergence of
Science & Business -
Convergence of
Science & Business -
Convergence of
Science & Business -
Convergence of
Science & Business
(유한양행 기술이전)AI 신약개발의 혁신 JIN-NOVA
J INTS BIO는 바이오 슈퍼컴 인프라를 최적화하고
신약 클라우드 환경을 구축하여 후보 물질을
지속적으로 도출하고 있습니다.
J INTS BIO의 지속가능한 경영을 위한 경영인증 및 시스템
-
ISO 9001:2015품질경영시스템 인증
신뢰할 수 있는 품질, 지속적인 개선
JINTS BIO는 ISO 9001 인증을 통해 체계적인 품질관리와 지속적 개선으로 고객 만족을 실현하고 있습니다.
-
ISO 37001:2016부패방지경영시스템 인증
윤리와 투명성, 글로벌 수준의 청렴 경영
JINTS BIO는 ISO 37001 인증을 통해 부패 리스크를 예방하고 윤리·투명 경영 체계를 운영하고 있습니다.
-
ISO 37301:2021준법경영시스템 인증
법과 윤리를 지키는 지속가능한 경영
JINTS BIO는 ISO 37301 인증을 통해 법규 준수와 책임 있는 준법경영을 실천하고 있습니다.
Notice&News
자세히 보기
공지&뉴스
-
NoticeJ INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observedSEOUL, South Korea, June 2, 2025 /PRNewswire/ -- J INTS BIO, a company spec 2025-06-02 -
Notice
J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025
SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in anticancer and orphan drugs, announced its research findings 2025-04-30 -
Notice
J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy
- Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST Professor Joung Ho Kim join a pioneering collaboration in pre 2024-12-15 -
Notice
J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy
SEOUL, South Korea, Oct. 24, 2024 /PRNewswire/ -- J INTS BIO, a pioneering biopharmaceutical company, has unveiled promising interim results from the 2024-10-24 -
Notice
J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance
SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- J INTS BIO, a leader in oncology drug development, has revealed interim preclinical results of its s 2024-10-23 -
Notice
J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- J INTS BIO provided an update of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGF 2024-06-10 -
Notice
J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study
SEOUL, South Korea, April 11, 2024 /PRNewswire/ -- J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation 2024-04-12 -
Notice
J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)
SEOUL, South Korea, Feb. 26, 2024 /PRNewswire/ -- J INTS BIO announced on the 26th of month that the Phase 1/2 clinical study of its Novel Oral 4th Ge 2024-02-26 -
Notice
J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023
'JIN-A02', a 4th generation EGFR-TKI, is a substance that selectively binds to C797S, a mutation that leads to resistance to 3rd generation EGFR-TKIs 2024-01-01 -
Notice
J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI
JIN-A02, a 4th generation EGFR TKI, selectively and reversibly binds to EGFR mutations, in particular C797S mutation that led to resistance to Osimert 2024-01-01
